
|Articles|November 1, 2004
Plans review pediatric antidepressant use in wake of FDA label change
By withholding information about some antidepressant medications that cause an increase in suicidal tendencies among teenagers, the Food and Drug Administration (FDA) created heightened public concern about the value of antidepressants.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
TrumpRx launches; some experts question its long-term value
3
PBM reform. It has finally happened
4
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
5























